Holen Sie sich die Stockscreener-App
8.00
1.24%
-0.05
Schlusskurs vom Vortag:
$8.05
Offen:
$8.07
24-Stunden-Volumen:
40,946
Relative Volume:
0.97
Marktkapitalisierung:
$128.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.82M
KGV:
-0.3126
EPS:
-25.5891
Netto-Cashflow:
$-66.04M
1W Leistung:
+3.18%
1M Leistung:
+40.46%
6M Leistung:
+58.05%
1J Leistung:
+19.01%
1-Tages-Spanne:
$7.90
$8.2199
1-Wochen-Bereich:
$7.76
$8.22
52-Wochen-Spanne:
$3.3419
$9.99
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Firmenname
Elicio Therapeutics Inc
Sektor
Branche
Telefon
(857) 209-0050
Adresse
451 D STREET, 5TH FLOOR, BOSTON
Vergleichen Sie ELTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
7.905 | 128.30M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
511.79 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.15 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
257.38 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Elicio Therapeutics Inc Aktie (ELTX) Neueste Nachrichten
Elicio Therapeutics Secures Strategic Financing As Pivotal Cancer Trial Data Approaches - Barchart.com
Elicio Therapeutics to Host Virtual KOL Event on June 25, - GlobeNewswire
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer - GlobeNewswire Inc.
Elicio secures $10 million to extend cash runway By Investing.com - Investing.com South Africa
Elicio Therapeutics Secures $10 Million in Financing - citybiz
Elicio Therapeutics Gets $10 Million Note Financing - marketscreener.com
Elicio secures $10 million to extend cash runway - Investing.com
Elicio Therapeutics Secures $10M Financing for Operations - TipRanks
Elicio Therapeutics (ELTX) Secures $10M Financing to Extend Operations | ELTX Stock News - GuruFocus
Elicio Therapeutics Lands $10M Funding to Advance Revolutionary Cancer Vaccine Through Critical Trial Phase - Stock Titan
When the Price of (ELTX) Talks, People Listen - news.stocktradersdaily.com
Elicio Therapeutics announces board election results By Investing.com - Investing.com Nigeria
Elicio Therapeutics Elects New Directors at Annual Meeting - TipRanks
Elicio Therapeutics announces board election results - Investing.com
Elicio Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Elicio's (ELTX) ELI-002 Interim Analysis Anticipated in Phase 2 Trial | ELTX Stock News - GuruFocus
Elicio Therapeutics: Q1 Earnings Snapshot - CTPost
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Learn to Evaluate (ELTX) using the Charts - news.stocktradersdaily.com
Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Long Term Trading Analysis for (ELTX) - news.stocktradersdaily.com
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires - GlobeNewswire
Key Executive Appointment: Elicio Therapeutics Names New Chief Strategy and Financial Officer - Stock Titan
Elicio Therapeutics grants inducement award to new chief strategy and financial officer - MSN
(ELTX) Investment Report - news.stocktradersdaily.com
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know - MSN
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Earnings Preview: What To Expect From Johnson & Johnson's Report - Barchart.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Elicio Therapeutics Advances Cancer Immunotherapy Pipeline - TipRanks
Elicio signals delay in mid-stage cancer vaccine study; shares slump - TradingView
Elicio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Elicio Therapeutics, Inc. SEC 10-K Report - TradingView
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Elicio's Latest Financial Results Reveal Key Clinical Milestones and 28.9-Month Survival Data - Stock Titan
(ELTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
ELICIO THERAPEUTICS Earnings Preview: Recent $ELTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Elicio Therapeutics Names Preetam Shah CFO -March 24, 2025 at 08:17 am EDT - MarketScreener
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewswire
Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch
Elicio Therapeutics Appoints New Chief Strategy and Financial Officer - TipRanks
Elicio Therapeutics appoints new CSFO amid clinical trials - Investing.com
Strategic Move: Elicio Strengthens Leadership Team Ahead of Crucial Phase 2 Trial Results - Stock Titan
Elicio Therapeutics, Inc. (NASDAQ:ELTX) surges 13%; individual investors who own 49% shares profited along with insiders - simplywall.st
Finanzdaten der Elicio Therapeutics Inc-Aktie (ELTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.66%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):